Last mentioned: Mar 6, 2026
Market Debut
MiniMed begins trading as an independent entity on the US exchange.
IPO Pricing
MiniMed prices 28 million shares at $20.00 per share, raising $560 million.
Pricing Finalized
The IPO prices at $560 million, falling below the initially marketed price range.
Analyst Debate
Market analysts debate the valuation of the diabetes unit amid competitive pressures.
Initial Filing
Medtronic's diabetes unit MiniMed seeks up to $784 million in U.S. IPO.
IPO Filing
MiniMed Group Inc. files S-1 registration statement for a US initial public offering.
Strategic Review
Medtronic announces intent to spin off its diabetes business unit to focus on core medtech.
Medtronic plc has priced the initial public offering of its diabetes-focused subsidiary, MiniMed Group Inc., at $20.00 per share for 28 million shares. The $560 million carve-out aims to provide the specialized unit with independent capital to compete in the high-growth insulin delivery and monitoring market.
Medtronic’s diabetes subsidiary, MiniMed Group Inc., has priced its initial public offering at $20.00 per share, successfully raising $560 million. The offering of 28 million shares comes in below initial valuation targets but marks a significant strategic pivot for parent company Medtronic plc.
Medtronic has successfully spun off its diabetes management business, MiniMed Group Inc., raising $560 million in a US IPO. Despite the significant capital raise, the offering priced below the initial marketed range, reflecting investor scrutiny of the competitive diabetes technology landscape.